Dr. Bendell on Exciting Advancements in the Field of HCC

Video

Johanna C. Bendell, MD, director of GI Oncology Research at Sarah Cannon Research Institute, discusses exciting research and advancements in the field of hepatocellular carcinoma.

Johanna C. Bendell, MD, director of GI Oncology Research at Sarah Cannon Research Institute, discusses exciting research and advancements in the field of hepatocellular carcinoma (HCC).

Researchers in the field have known that drugs that block the angiogenesis pathway for patients with HCC, such as sorafenib (Nexavar), do work for these patients, Bendell explains. However, data presented from the phase III RESORCE trial show that the multikinase inhibitor regorafenib (Stivarga) also has a benefit in this population.

Immunotherapies are also agents with potential, she adds. In liver cancer, investigators have looked at checkpoint inhibitors like anti­—PD-1/PD-L1 agents alone and in combination with CTLA-4 inhibitors. These types of combinations are currently being explored in clinical trials; moreover, they are showing particular potential in patients with hepatitis C.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD
Saad J. Kenderian, MB, CHB, consultant, Division of Hematology, Department of Internal Medicine, Department of Immunology, Department of Molecular Medicine, assistant professor, oncology, immunology, medicine, Mayo Clinic
Mary-Ellen Taplin, MD